Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Lumos Diagnostics Holdings Limited

Healthcare US LDXHF

0.22USD
-(-%)

Last update at 2026-03-09T20:00:00Z

Day Range

0.220.22
LowHigh

52 Week Range

0.00920.10
LowHigh

Fundamentals

  • Previous Close 0.22
  • Market Cap23.51M
  • Volume4000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.07400M
  • Revenue TTM10.54M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM 5.32M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -8.97100M -45.72400M - - -
Minority interest - - - - -
Net income -8.97100M -45.72400M - - -
Selling general administrative 10.22M 16.86M - - -
Selling and marketing expenses - 2.27M - - -
Gross profit 5.97M 4.46M - - -
Reconciled depreciation 3.67M 2.82M - - -
Ebit -10.23600M -21.49400M -11.00200M -15.53300M -4.11323M
Ebitda -4.92900M -18.67100M - - -
Depreciation and amortization - 2.82M - - -
Non operating income net other - - - - -
Operating income -9.52700M -21.49400M - - -
Other operating expenses - 32.70M 0.66M 0.66M 0.08M
Interest expense 0.37M 0.17M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M - - -
Interest income 0.02M - - - -
Net interest income -0.79100M -0.61000M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.19M - -0.08600M -0.87064M
Total revenue 10.54M 11.63M - - -
Total operating expenses - 25.53M - - -
Cost of revenue 4.56M 7.17M - - -
Total other income expense net 1.35M -24.04100M - - -
Discontinued operations - - - - -
Net income from continuing ops -8.97100M -45.72400M - - -
Net income applicable to common shares -8.97100M -45.72400M -15.03000M -13.44700M -6.54585M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 25.42M 36.94M - - -
Intangible assets 10.89M 12.53M - - -
Earning assets - - - - -
Other current assets - 1.05M - 0.03M -
Total liab 15.92M 19.05M - - -
Total stockholder equity 9.50M 17.89M - - -
Deferred long term liab 7.19M 8.15M 8.76M 8.75M 5.62M
Other current liab 3.46M 10.41M 25.21M 1.90M 2.57M
Common stock 92.47M 92.14M 84.22M 23.13M 18.09M
Capital stock 92.47M 92.14M - - -
Retained earnings -82.29200M -74.53400M -28.81000M -20.03700M -6.58981M
Other liab - - - - -
Good will - - - - -
Other assets 7.19M 8.15M 8.76M 8.83M 5.62M
Cash 3.02M 7.98M - - -
Cash and equivalents - - - - -
Total current liabilities 8.17M 12.83M 32.51M 7.07M 4.73M
Current deferred revenue - 3.75M - - -
Net debt - -0.78400M - - -
Short term debt - 0.97M - - -
Short long term debt 1.35M - - - -
Short long term debt total - 7.19M - - -
Other stockholder equity -0.67800M 0.28M 2.87M 1.46M 5.11M
Property plant equipment 8.56M 10.97M 14.88M 6.84M 0.81M
Total current assets 5.96M 13.44M 57.06M 5.31M 6.71M
Long term investments - - - - -
Net tangible assets 5.80M 13.50M 41.20M -18.06300M -6.15722M
Short term investments - - - - -
Net receivables 1.49M 1.89M 4.25M 1.35M 2.06M
Long term debt - - - - -
Inventory 1.06M 2.53M 4.44M 0.73M 0.11M
Accounts payable 1.14M 1.45M 4.56M 3.32M 0.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.28M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 19.45M 23.50M - - -
Capital lease obligations 8.44M 7.19M - - -
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 4.31M -4.35500M - - -0.27056M
Change to liabilities -6.17800M -3.09500M 8.33M 0.67M 2.68M
Total cashflows from investing activities 4.31M -4.35500M -8.33200M -9.44600M -11.72585M
Net borrowings 0.79M -1.20600M 16.26M -0.23600M 19.99M
Total cash from financing activities 0.65M -10.91900M 63.27M 11.76M 19.99M
Change to operating activities 0.50M 1.54M -0.47900M 0.22M -1.14586M
Net income -8.97100M -45.72400M -15.03000M -13.44700M -6.54585M
Change in cash -4.96300M -36.91200M 44.04M -3.13900M 4.04M
Begin period cash flow 7.98M 44.89M - - -
End period cash flow 3.02M 7.98M 44.89M - -
Total cash from operating activities -9.63800M -18.03600M -10.88900M -5.44500M -4.32259M
Issuance of capital stock - 7.87M - - -
Depreciation 3.03M 2.42M 0.45M 0.58M 0.18M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.81M -1.35400M -3.93900M -0.71800M -0.05990M
Change to account receivables 0.93M -0.18000M -3.32600M 0.60M -1.63662M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.13400M -18.78900M 17.58M 17.58M 17.58M
Change to netincome -0.73700M 27.95M 3.01M 6.44M 1.71M
Capital expenditures 0.12M 4.36M 5.88M 9.45M 3.60M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow -9.79300M -4.35500M - - -

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LDXHF
Lumos Diagnostics Holdings Limited		 - -% 0.22 - - 2.13 2.80 2.51 -5.3643
TMO
Thermo Fisher Scientific Inc		 -9.89 1.94% 500.08 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -3.58 1.80% 195.22 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -1.21 1.04% 115.43 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -11.6 1.90% 598.85 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Lumos Diagnostics Holdings Limited, a contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. The company's products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.

Lumos Diagnostics Holdings Limited

Level 4, Melbourne, VIC, Australia, 3205

Key Executives

Name Title Year Born
Mr. Samuel Lanyon Exec. Chairman NA
Mr. Douglas Ward Chief Exec. Officer NA
Mr. Barrie Lambert Chief Financial Officer NA
Dr. Sacha Dopheide Ph.D. Chief Technology Officer NA
Ms. Jennifer Christiansen VP of Corp. Marketing & Communications NA
Ms. Sarah Glubka Sr. Director of HR NA
Ms. Annie Bell Sr. Director of Medical Affairs NA
Ms. Sue Hibbeln Sr. Director of Regulatory Affairs NA
Mr. Paul Kase Sr. VP of Commercial Operations NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA Company Sec. 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.